Neoadjuvant Chemoimmunotherapy Clinical Trials

13 recruiting

Neoadjuvant Chemoimmunotherapy Trials at a Glance

13 actively recruiting trials for neoadjuvant chemoimmunotherapy are listed on ClinicalTrialsFinder across 6 cities in 6 countries. The largest study group is Phase 2 with 7 trials, with the heaviest enrollment activity in Wuhan, Guangzhou, and Cosenza. Lead sponsors running neoadjuvant chemoimmunotherapy studies include Tongji Hospital, Shanghai Chest Hospital, and Guo Xufeng.

Browse neoadjuvant chemoimmunotherapy trials by phase

Treatments under study

About Neoadjuvant Chemoimmunotherapy Clinical Trials

Looking for clinical trials for Neoadjuvant Chemoimmunotherapy? There are currently 13 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Neoadjuvant Chemoimmunotherapy trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Neoadjuvant Chemoimmunotherapy clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 113 of 13 trials

Recruiting

Imaging-based PRediction of Eligibility for ChemoImmunotherapy in reSEctable NSCLC, iPRECISE

NSCLCNeoadjuvant ChemoimmunotherapyCT
Samsung Medical Center150 enrolled1 locationNCT07559123
Recruiting

RATS Sleeve Lobectomy After Neo-Chemo-IO for NSCLC

Robotic SurgeryStage IIB-III NSCLCNeoadjuvant Chemoimmunotherapy+1 more
Shanghai Chest Hospital100 enrolled10 locationsNCT07541521
Recruiting

Downstaging and RATS After Neo-Chemo-IO: Impact on Surgical Outcomes in NSCLC

Stage IIB-III NSCLCNeoadjuvant ChemoimmunotherapyRobotic Pulmonary Resection
Shanghai Chest Hospital200 enrolled10 locationsNCT07528066
Recruiting
Not Applicable

Tumor Margin Skin Tattooing Before Neo-adjuvant Chemotherapy in Patients With Breast Cancer

Breast Cancer (Locally Advanced or Metastatic)Neoadjuvant ChemoimmunotherapyTattoo Skin Markers
All India Institute of Medical Sciences, Bhubaneswar30 enrolled1 locationNCT07478900
Recruiting
Phase 2

Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05)

Neoadjuvant TherapyRadiotherapyImmunotherapy+2 more
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University40 enrolled1 locationNCT07165847
Recruiting
Phase 1Phase 2

NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study

Mesothelioma; PleuraNeoadjuvant ChemoimmunotherapyPleural Epithelioid Mesothelioma
University Hospital, Antwerp37 enrolled1 locationNCT07121374
Recruiting
Phase 2

Neoadjuvant Immunochemotherapy in PD-L1-negative LACC

Cervical CancerNeoadjuvant ChemoimmunotherapyLocally Advanced Cervical Cancer+1 more
Tongji Hospital40 enrolled12 locationsNCT06288360
Recruiting
Phase 2

Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer

Cervical CancerFertility PreservationNeoadjuvant Chemoimmunotherapy
Tongji Hospital40 enrolled2 locationsNCT06289062
Recruiting
Phase 2Phase 3

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Cervical CancerConcurrent ChemoradiotherapyNeoadjuvant Chemoimmunotherapy+1 more
Tongji Hospital440 enrolled12 locationsNCT06288373
Recruiting
Phase 2

Neoadjuvant Chemoimmunotherapy and Extrafascial Hysterectomy for IB2 Cervical Cancer

Cervical CancerNeoadjuvant ChemoimmunotherapyRadical Hysterectomy+1 more
Tongji Hospital50 enrolled2 locationsNCT06289751
Recruiting

Mechanism Study to Investigate Difference in Efficacy of Neoadjuvant Chemoimmunotherapy in Lung Squamous Cell Carcinoma

Lung Squamous Cell CarcinomaTumor MicroenvironmentNeoadjuvant Chemoimmunotherapy
Tang-Du Hospital40 enrolled1 locationNCT06436040
Recruiting
Phase 2

Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma

Esophageal Squamous Cell CarcinomaAdjuvant TherapyNeoadjuvant Chemoimmunotherapy
Guo Xufeng73 enrolled1 locationNCT06056336
Recruiting

Neoadjuvant Anti-PD-1 Plus Chemotherapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

Esophageal Squamous Cell CarcinomaNeoadjuvant Chemoimmunotherapy
Shanghai Zhongshan Hospital40 enrolled1 locationNCT05740995